I think there is a lot of confusion, especially in the patient community, about clinical research., explained Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network.
I think there is a lot of confusion, especially in the patient community, about clinical research, explained Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network.
Transcript
When offering clinical trials to patients, does this require dispelling misconceptions they might have about participating in a trial?
I think there is a lot of confusion, especially in the patient community, about clinical research. A lot of patients I think hear clinical research thinking they’re going to be some sort of guinea pig. They don’t know if it’s a real drug or a placebo or whatever the case may be. We’ve had so many patients that have been enrolled in clinical trials that were not progressing well with standard of care that they’ve had incredible outcomes. I think one of our goals is continuing to try and educate patients on what is clinical research and really dumbing it down because even people that are in healthcare, I think, often times have misconceptions about what clinical research really is.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More